Last week, we attended the NASH-TAG conference in beautiful Park City, Utah. Against a winter wonderland backdrop, we dove deep into the latest research on metabolic associated steatohepatitis (MASH, also known as non-alcoholic steatohepatitis or NASH) and connected with leading experts in the field. Here, we’ll share some of our key learnings, underscoring the evolving landscape of liver disease research.
In the ever-changing field of precision medicine, continuous evaluation of data sharing and collaboration practices is essential for biotech and pharma companies. This ongoing assessment is vital to ensure compliance with evolving regulations, protect patient privacy, and foster innovative research. Drawing from our expertise in this area, we've created a straightforward checklist to help these companies responsibly handle genetic and biomarker data and collaborate effectively with third parties.
Drug development remains one of the most complex, costly, and failure-prone processes in the life sciences. Traditional approaches rely heavily on trial-and-error experimentation, sequential decision-making, and fragmented data. The emergence of AI, including large language models and generative AI, is beginning to reshape this process, not by replacing human expertise, but by augmenting it across the entire development workflow, from target identification through post-market surveillance.
As the new year unfolds, it's a time for reflection on some of the most inspirational stories in human genetics last year, and anticipation of what's to come in this area in 2024.
In the two decades since the first human genome sequencing, technological progress has unlocked an enormous collection of genetic data. This invaluable resource has deepened our understanding of DNA's role in diseases and the diverse genetic makeup among individuals. However, a significant caveat exists: a disproportionate amount of this data stems from individuals of European descent. As of 2021, over 86% of genomic data hails from this group, with East Asians contributing around 6%, Africans 1%, and all other demographics less than 1%. This skew in data collection limits the potential benefits of genomic research for underrepresented populations. And one issue at the heart of it is a lack of genomic literacy.
Genetic variation across populations has direct consequences for precision medicine trial design. As patient populations in clinical research become more ethnically and culturally diverse, cultural competency in genomic medicine is a structural requirement for equitable and effective trial execution. This diversity is characterized by distinct cultural backgrounds that considerably influence individuals' reactions to various healthcare services, including the progressively important field of genomic medicine. In this context, cultural competency becomes an essential skill for researchers and healthcare providers. When applied consistently, cultural competence reduces variation in care delivery, improves patient trust, and supports more accurate clinical and genomic decision-making across diverse populations.
Health equity, defined as everyone having the opportunity to be as healthy as possible, has long been a primary goal of public health. Still, across the world, people don't have the same opportunities to see doctors, take part in research, or access medications and genetic testing. This disparity of care can affect rates of disease and disability – and most importantly, hinder quality and length of life.
Our new whitepaper "Inclusive genomics: A path to equitable precision medicine" offers a close look at the intersection of genomic research and diversity. It's an exploration of how embracing the full spectrum of human diversity is not just beneficial but essential for the advancement of precision medicine.
The 34th International Symposium on ALS/MND arrived at a moment of real momentum in ALS research. The field has seen a significant expansion in genetic understanding, growing investment, and the emergence of the first genetically targeted therapies. This year's event underscored that trajectory, commemorating the 30th anniversary of the discovery of SOD1, the first monogenic cause of ALS, and making clear how far the genetic understanding of this disease has come.
As we step into a new era of medical innovation, it's crucial to shine a light on diseases that have long remained in the shadows. Amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease also known as motor neuron disease (MND), is one such condition that has challenged medical experts for decades. Today, we’re thrilled to share a beacon of hope in this challenging landscape: Sano’s launch of “Light the Way.”